Literature DB >> 8882168

Relaxin stimulates atrial natriuretic peptide secretion in perfused rat heart.

M Toth1, P Taskinen, H Ruskoaho.   

Abstract

Relaxin, a reproductive hormone of the insulin-like growth factor family, increases heart rate in experimental animals but its other actions on cardiac function and cellular mechanisms responsible for the positive chronotrophic effect remain unknown. We have studied the actions of human recombinant gene-2 relaxin on the release of atrial natriuretic peptide (ANP) and cardiac function (heart rate, contractile force, perfusion pressure) as well as the underlying signal transduction mechanisms by using the isolated perfused spontaneously beating rat heart preparation. The administration of relaxin into the perfusion fluid at concentrations of 1.5, 3 or 10 nM for 30 min caused a dose-dependent sustained increase in heart rate, while contractile force and perfusion pressure remained unchanged. In addition, infusion of relaxin at a concentration of 10 nM into the perfusate produced a gradual 1.5-fold increase in immunoreactive ANP (IR-ANP) secretion (from 456 +/- 76 to 701 +/- 124 pg/ml, F = 4.5, P < 0.001). The ANP secretory and chronotrophic effects of relaxin appear to involve the activation of protein kinase C, since administration of a protein kinase C inhibitor staurosporine at a concentration of 30 nM completely blocked the effect of relaxin (10 nM) on IR-ANP secretion (P < 0.001) and heart rate (P < 0.001). A cAMP-dependent protein kinase inhibitor, H-89 (100 nM), also substantially reduced the ANP secretory effect of relaxin and attenuated the increase in heart rate during the sustained phase of the relaxin infusion (P < 0.001). KN-62 (3 microM), a Ca2+/calmodulin-dependent protein kinase inhibitor, decreased the positive chronotrophic effect of relaxin (P < 0.001) but did not influence significantly the effect of relaxin on IR-ANP release in isolated perfused rat heart preparation. These results provide the first evidence that relaxin stimulates the secretion of ANP from isolated perfused rat hearts. Our results also suggest that relaxin modulates ANP secretion by activation of protein kinase C and cAMP-dependent protein kinase pathways.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8882168     DOI: 10.1677/joe.0.1500487

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  11 in total

Review 1.  Cardiovascular effects of relaxin: from basic science to clinical therapy.

Authors:  Xiao-Jun Du; Ross A D Bathgate; Chrishan S Samuel; Anthony M Dart; Roger J Summers
Journal:  Nat Rev Cardiol       Date:  2009-11-24       Impact factor: 32.419

Review 2.  The actions of relaxin on the human cardiovascular system.

Authors:  Mohsin Sarwar; Xiao-Jun Du; Thomas B Dschietzig; Roger J Summers
Journal:  Br J Pharmacol       Date:  2016-07-11       Impact factor: 8.739

3.  Inotropic responses to human gene 2 (B29) relaxin in a rat model of myocardial infarction (MI): effect of pertussis toxin.

Authors:  Andrew R Kompa; Chrishan S Samuel; Roger J Summers
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

Review 4.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

5.  Ligand-activated RXFP1 gene therapy ameliorates pressure overload-induced cardiac dysfunction.

Authors:  Nuttarak Sasipong; Philipp Schlegel; Julia Wingert; Christoph Lederer; Eric Meinhardt; Amelie Ziefer; Constanze Schmidt; Kleopatra Rapti; Cornelia Thöni; Norbert Frey; Patrick Most; Hugo A Katus; Philip W J Raake
Journal:  Mol Ther       Date:  2021-04-09       Impact factor: 12.910

6.  The cardiovascular effects of porcine relaxin in Brattleboro rats.

Authors:  L J Parry; B C Wilson; R S Poterski; A J Summerlee
Journal:  Endocrine       Date:  1998-06       Impact factor: 3.925

Review 7.  Relaxin, a pleiotropic vasodilator for the treatment of heart failure.

Authors:  Sam L Teichman; Elaine Unemori; Thomas Dschietzig; Kirk Conrad; Adriaan A Voors; John R Teerlink; G Michael Felker; Marco Metra; Gad Cotter
Journal:  Heart Fail Rev       Date:  2008-12-20       Impact factor: 4.214

Review 8.  Vasodilators in the treatment of acute heart failure: what we know, what we don't.

Authors:  Marco Metra; John R Teerlink; Adriaan A Voors; G Michael Felker; Olga Milo-Cotter; Beth Weatherley; Howard Dittrich; Gad Cotter
Journal:  Heart Fail Rev       Date:  2008-12-19       Impact factor: 4.214

9.  Relaxin and atrial natriuretic peptide pathways participate in the anti-fibrotic effect of a melon concentrate in spontaneously hypertensive rats.

Authors:  Julie Carillon; Audrey Gauthier; Sandy Barial; Michel Tournier; Nathalie Gayrard; Anne-Dominique Lajoix; Bernard Jover
Journal:  Food Nutr Res       Date:  2016-04-12       Impact factor: 3.894

Review 10.  Relaxin-2 in Cardiometabolic Diseases: Mechanisms of Action and Future Perspectives.

Authors:  Sandra Feijóo-Bandín; Alana Aragón-Herrera; Diego Rodríguez-Penas; Manuel Portolés; Esther Roselló-Lletí; Miguel Rivera; José R González-Juanatey; Francisca Lago
Journal:  Front Physiol       Date:  2017-08-18       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.